首页 > 最新文献

Hypertension Research最新文献

英文 中文
Participating in hypertension Seoul 2025. 参加高血压首尔2025。
IF 4.6 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-16 DOI: 10.1038/s41440-025-02499-z
Masaki Mogi, Satoshi Hoshide, Kazuomi Kario
{"title":"Participating in hypertension Seoul 2025.","authors":"Masaki Mogi, Satoshi Hoshide, Kazuomi Kario","doi":"10.1038/s41440-025-02499-z","DOIUrl":"https://doi.org/10.1038/s41440-025-02499-z","url":null,"abstract":"","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145767901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation hypertension: a new paradigm for global hypertension control in the JSH 2025, WHO 2025, and AHA/ACC 2025 guideline era 实施高血压:JSH 2025、WHO 2025和AHA/ACC 2025指南时代全球高血压控制的新范式
IF 4.6 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-16 DOI: 10.1038/s41440-025-02497-1
Kazuomi Kario
{"title":"Implementation hypertension: a new paradigm for global hypertension control in the JSH 2025, WHO 2025, and AHA/ACC 2025 guideline era","authors":"Kazuomi Kario","doi":"10.1038/s41440-025-02497-1","DOIUrl":"10.1038/s41440-025-02497-1","url":null,"abstract":"","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"49 1","pages":"1-6"},"PeriodicalIF":4.6,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41440-025-02497-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145762745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intentional and unintentional non-adherence in hypertension: psychometric validation, adherence-complexity phenotyping and causal mediation analysis from the VATAHTA Study. 高血压患者有意和无意的不依从性:来自VATAHTA研究的心理测量验证、依从复杂性表型和因果中介分析
IF 4.6 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-16 DOI: 10.1038/s41440-025-02427-1
Nicolás F Renna, Jesica M Ramirez, Matias F Arrupe, Philip Magueflor Morisky

Non-adherence to antihypertensive therapy remains a major barrier to blood pressure (BP) control globally. The behavioural distinction between intentional (INA) and unintentional non-adherence (UNA) is underexplored in low- and middle-income countries. We aimed to validate the Spanish MMAS-8, identify adherence-complexity phenotypes, and assess the mediating role of adherence between regimen complexity and BP control. In this multicenter, cross-sectional study (2022-2024), 1144 hypertensive patients from Argentina were evaluated. Adherence was assessed using the Spanish MMAS-8. Psychometric validation included Cronbach's alpha and principal component analysis. INA and UNA were classified by domain-based response patterns. K-means clustering was applied to MMAS-8 items and regimen complexity (number of drugs, daily doses). Mediation analysis tested the indirect effect of adherence. The MMAS-8 showed acceptable reliability (α = 0.78) and a unidimensional structure. Full adherence was observed in 41.1%. Among non-adherent patients, 38.5% were INA, 33.6% UNA, and 27.9% mixed. Four phenotypes were identified: (1) high adherence/low complexity; (2) very low adherence/simple regimens; (3) moderate adherence/intermediate complexity; (4) low adherence/high complexity. Adherence significantly mediated the effect of complexity on BP control (β = 0.004; p < 0.001), while the direct effect was non-significant. Compared with phenotype 1, phenotype 2 showed 58% lower odds of control (OR 0.42; 95% CI 0.29-0.61) and phenotype 4 showed 32% lower odds (OR 0.68; 95% CI 0.49-0.94). The Spanish MMAS-8 is valid for this population. Adherence-complexity phenotypes reflect structural and behavioural barriers. Tailored interventions should address INA and UNA using adherence profiling, fixed-dose combinations, and social support.

在全球范围内,不坚持抗高血压治疗仍然是控制血压的主要障碍。在低收入和中等收入国家,有意(INA)和无意不遵守(UNA)之间的行为区别尚未得到充分探讨。我们的目的是验证西班牙MMAS-8,确定依从性复杂性表型,并评估依从性在方案复杂性和血压控制之间的中介作用。在这项多中心横断面研究(2022-2024)中,对来自阿根廷的1144例高血压患者进行了评估。使用西班牙MMAS-8评估依从性。心理测量验证包括Cronbach's α和主成分分析。根据基于域的响应模式对INA和UNA进行分类。采用K-means聚类分析MMAS-8项目和方案复杂性(药物数量、日剂量)。中介分析检验了依从性的间接影响。MMAS-8具有可接受的信度(α = 0.78)和单维结构。41.1%的患者完全依从。在非依从性患者中,38.5%为INA, 33.6%为UNA, 27.9%为混合。鉴定出四种表型:(1)高粘附/低复杂性;(2)依从性非常低/方案简单;(3)中等依从性/中等复杂性;(4)低依从性/高复杂性。依从性显著介导复杂性对血压控制的影响(β = 0.004
{"title":"Intentional and unintentional non-adherence in hypertension: psychometric validation, adherence-complexity phenotyping and causal mediation analysis from the VATAHTA Study.","authors":"Nicolás F Renna, Jesica M Ramirez, Matias F Arrupe, Philip Magueflor Morisky","doi":"10.1038/s41440-025-02427-1","DOIUrl":"https://doi.org/10.1038/s41440-025-02427-1","url":null,"abstract":"<p><p>Non-adherence to antihypertensive therapy remains a major barrier to blood pressure (BP) control globally. The behavioural distinction between intentional (INA) and unintentional non-adherence (UNA) is underexplored in low- and middle-income countries. We aimed to validate the Spanish MMAS-8, identify adherence-complexity phenotypes, and assess the mediating role of adherence between regimen complexity and BP control. In this multicenter, cross-sectional study (2022-2024), 1144 hypertensive patients from Argentina were evaluated. Adherence was assessed using the Spanish MMAS-8. Psychometric validation included Cronbach's alpha and principal component analysis. INA and UNA were classified by domain-based response patterns. K-means clustering was applied to MMAS-8 items and regimen complexity (number of drugs, daily doses). Mediation analysis tested the indirect effect of adherence. The MMAS-8 showed acceptable reliability (α = 0.78) and a unidimensional structure. Full adherence was observed in 41.1%. Among non-adherent patients, 38.5% were INA, 33.6% UNA, and 27.9% mixed. Four phenotypes were identified: (1) high adherence/low complexity; (2) very low adherence/simple regimens; (3) moderate adherence/intermediate complexity; (4) low adherence/high complexity. Adherence significantly mediated the effect of complexity on BP control (β = 0.004; p < 0.001), while the direct effect was non-significant. Compared with phenotype 1, phenotype 2 showed 58% lower odds of control (OR 0.42; 95% CI 0.29-0.61) and phenotype 4 showed 32% lower odds (OR 0.68; 95% CI 0.49-0.94). The Spanish MMAS-8 is valid for this population. Adherence-complexity phenotypes reflect structural and behavioural barriers. Tailored interventions should address INA and UNA using adherence profiling, fixed-dose combinations, and social support.</p>","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145767891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of exercise and physical activity on blood pressure reduction. 运动和体育活动对降低血压的影响。
IF 4.6 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-16 DOI: 10.1038/s41440-025-02491-7
Ayumi Toba

Exercise and physical activity are known to have a positive effect on antihypertensive and cardiovascular risk reduction. Combination of different types of exercise: aerobic exercise and resistance exercise is reported to have comprehensive cardiovascular benefits than either training alone. Appropriate types of exercise vary depending on the individual's age, gender, underlying disease, and activity level. Maintaining a robust physical state through exercise is critical for preventing cognitive decline or in-hospital death in cases of heart failure.

众所周知,锻炼和体育活动对抗高血压和降低心血管风险有积极作用。不同类型运动的组合:有氧运动和抗阻运动据报道比单独训练有全面的心血管益处。适当的运动类型取决于个人的年龄、性别、潜在疾病和活动水平。通过锻炼保持强健的身体状态对于预防认知能力下降或心力衰竭患者的住院死亡至关重要。
{"title":"Effect of exercise and physical activity on blood pressure reduction.","authors":"Ayumi Toba","doi":"10.1038/s41440-025-02491-7","DOIUrl":"https://doi.org/10.1038/s41440-025-02491-7","url":null,"abstract":"<p><p>Exercise and physical activity are known to have a positive effect on antihypertensive and cardiovascular risk reduction. Combination of different types of exercise: aerobic exercise and resistance exercise is reported to have comprehensive cardiovascular benefits than either training alone. Appropriate types of exercise vary depending on the individual's age, gender, underlying disease, and activity level. Maintaining a robust physical state through exercise is critical for preventing cognitive decline or in-hospital death in cases of heart failure.</p>","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145767689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on "Lower high-density lipoprotein cholesterol level is associated with hematoma expansion in acute intracerebral hemorrhage: association with hypertensive microangiopathy". 对“低高密度脂蛋白胆固醇水平与急性脑出血血肿扩张有关:与高血压微血管病有关”的评论。
IF 4.6 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-12 DOI: 10.1038/s41440-025-02471-x
Haimao Xie, XiaoXiao Zhang, Ai Xie
{"title":"Comment on \"Lower high-density lipoprotein cholesterol level is associated with hematoma expansion in acute intracerebral hemorrhage: association with hypertensive microangiopathy\".","authors":"Haimao Xie, XiaoXiao Zhang, Ai Xie","doi":"10.1038/s41440-025-02471-x","DOIUrl":"https://doi.org/10.1038/s41440-025-02471-x","url":null,"abstract":"","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145742273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of morning or evening antihypertensive therapy on heart failure in community resident patients: Results of the TIME and BedMed Trials. 早晨或晚上降压治疗对社区住院患者心力衰竭的影响:TIME和BedMed试验的结果
IF 4.6 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-10 DOI: 10.1038/s41440-025-02483-7
Francesca Coccina, Sante D Pierdomenico

To evaluate the effect of morning or evening antihypertensive therapy on heart failure (HF), myocardial infarction, stroke and all-cause death in community resident patients in the TIME and BedMed trials, by study-level meta-analysis. These trials included 24,461 patients, experiencing 248 HFs, 371 myocardial infarctions, 331 strokes and 1,044 all-cause deaths. The pooled hazard ratio (HR) and 95% confidence interval (CI) between therapy groups were calculated for each event. For HF, myocardial infarction, stroke and all-cause death, the HRs (95%) CIs, P value, for evening versus morning therapy were 0.77 (0.60-0.99), P = 0.04, 1.02 (0.77-1.35), P = 0.91, 0.92 (0.74-1.14), P = 0.43, and 1.02 (0.90-1.14), P = 0.79, respectively. No heterogeneity was found for HF, stroke and all-cause death, and mild heterogeneity was observed for myocardial infarction. In the TIME and BedMed trials, compared to morning therapy, evening therapy was associated with a 23% lower risk of HF, whereas no difference was observed for other outcomes. This analysis of the TIME and BedMed trials evaluating community resident patients shows that, when compared to morning antihypertensive therapy, evening therapy was associated with a 23% lower risk of HF. CI confidence interval, HR hazard ratio.

通过研究水平的荟萃分析,评价早晚降压治疗对TIME和BedMed试验中社区住院患者心力衰竭(HF)、心肌梗死、卒中和全因死亡的影响。这些试验包括24,461例患者,经历248例hf, 371例心肌梗死,331例中风和1,044例全因死亡。计算各事件治疗组间的合并危险比(HR)和95%可信区间(CI)。对于心衰、心肌梗死、卒中和全因死亡,晚间治疗与上午治疗的hr (95%) ci, P值分别为0.77(0.60-0.99)、P = 0.04、1.02(0.77-1.35)、P = 0.91、0.92(0.74-1.14)、P = 0.43和1.02 (0.90-1.14),P = 0.79。心衰、卒中和全因死亡无异质性,心肌梗死有轻度异质性。在TIME和BedMed试验中,与早上治疗相比,晚上治疗与HF风险降低23%相关,而其他结果没有观察到差异。对TIME和BedMed评估社区住院患者试验的分析表明,与早晨降压治疗相比,晚上降压治疗与心衰风险降低23%相关。CI置信区间,HR风险比。
{"title":"Effect of morning or evening antihypertensive therapy on heart failure in community resident patients: Results of the TIME and BedMed Trials.","authors":"Francesca Coccina, Sante D Pierdomenico","doi":"10.1038/s41440-025-02483-7","DOIUrl":"https://doi.org/10.1038/s41440-025-02483-7","url":null,"abstract":"<p><p>To evaluate the effect of morning or evening antihypertensive therapy on heart failure (HF), myocardial infarction, stroke and all-cause death in community resident patients in the TIME and BedMed trials, by study-level meta-analysis. These trials included 24,461 patients, experiencing 248 HFs, 371 myocardial infarctions, 331 strokes and 1,044 all-cause deaths. The pooled hazard ratio (HR) and 95% confidence interval (CI) between therapy groups were calculated for each event. For HF, myocardial infarction, stroke and all-cause death, the HRs (95%) CIs, P value, for evening versus morning therapy were 0.77 (0.60-0.99), P = 0.04, 1.02 (0.77-1.35), P = 0.91, 0.92 (0.74-1.14), P = 0.43, and 1.02 (0.90-1.14), P = 0.79, respectively. No heterogeneity was found for HF, stroke and all-cause death, and mild heterogeneity was observed for myocardial infarction. In the TIME and BedMed trials, compared to morning therapy, evening therapy was associated with a 23% lower risk of HF, whereas no difference was observed for other outcomes. This analysis of the TIME and BedMed trials evaluating community resident patients shows that, when compared to morning antihypertensive therapy, evening therapy was associated with a 23% lower risk of HF. CI confidence interval, HR hazard ratio.</p>","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145722394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fibrosis-4 index and prognosis and hematoma volume: association with lobar and non-lobar intracerebral hemorrhage. 纤维化-4指数、预后和血肿体积:与大叶性和非大叶性脑出血的关系。
IF 4.6 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-10 DOI: 10.1038/s41440-025-02487-3
Takeo Sato, Yuka Tsuchimochi, Yuki Hamada, Kaishi Kukihara, Yutaro Kawabata, Kana Iwamoto, Go Takaguchi, Yujiro Higuchi, Hideki Matsuoka, Hiroshi Takashima

Liver fibrosis is a proposed risk factor for intracerebral hemorrhage (ICH) and a predictor of ICH-related mortality. However, its impact on functional outcomes and hemorrhage location remains unclear. We aimed to investigate whether liver fibrosis is associated with clinical outcomes and hematoma characteristics according to ICH location. Consecutive patients with ICH between July 2012 and November 2023 were retrospectively included. Favorable outcomes were defined as a modified Rankin Scale score of 0 to 1 at 3 months following stroke onset. We elucidated whether liver fibrosis, assessed by the Fibrosis-4 index (FIB-4 index), was associated with prognosis and hematoma volume in the entire ICH cohort, and separately in lobar and non-lobar ICH cohorts. Following screening of 608 consecutive ICH patients, 356 patients with ICH (entire cohort) who met the inclusion criteria (198 [56%] males, median age 73 years), including 69 with lobar ICH and 287 patients with non-lobar ICH, were identified. Similar to the entire ICH cohort, especially in the lobar ICH cohort, the FIB-4 index correlated negatively with favorable outcomes (prevalence ratio (PR) 0.823, 95% confidence interval (CI) 0.692-0.979, p = 0.027) and positively with hematoma volume (unstandardized coefficient 3.914, 95% CI 1.914-5.915, p < 0.001). Conversely, the FIB-4 index was associated with neither prognosis nor hematoma volume in the non-lobar ICH cohort. Liver fibrosis, as assessed by the FIB-4 index, is associated with unfavorable outcomes and hematoma volume in ICH, particularly in lobar ICH.

肝纤维化被认为是脑出血(ICH)的危险因素,也是脑出血相关死亡率的预测因子。然而,其对功能结局和出血部位的影响尚不清楚。我们的目的是研究肝纤维化是否与脑出血部位的临床结果和血肿特征相关。回顾性纳入2012年7月至2023年11月连续的脑出血患者。卒中发作后3个月的修正Rankin量表评分为0到1分。我们通过纤维化-4指数(FIB-4指数)评估肝纤维化是否与整个脑出血队列的预后和血肿量相关,并分别在大叶性和非大叶性脑出血队列中进行了研究。通过对608例连续脑出血患者的筛查,确定了356例脑出血患者(整个队列)符合纳入标准(198例[56%]男性,中位年龄73岁),其中69例为大叶性脑出血,287例为非大叶性脑出血。与整个脑出血队列,特别是大叶脑出血队列相似,FIB-4指数与预后呈负相关(患病率比(PR) 0.823, 95%可信区间(CI) 0.692-0.979, p = 0.027),与血肿体积呈正相关(非标准化系数3.914,95% CI 1.914-5.915, p . 0.027)
{"title":"Fibrosis-4 index and prognosis and hematoma volume: association with lobar and non-lobar intracerebral hemorrhage.","authors":"Takeo Sato, Yuka Tsuchimochi, Yuki Hamada, Kaishi Kukihara, Yutaro Kawabata, Kana Iwamoto, Go Takaguchi, Yujiro Higuchi, Hideki Matsuoka, Hiroshi Takashima","doi":"10.1038/s41440-025-02487-3","DOIUrl":"https://doi.org/10.1038/s41440-025-02487-3","url":null,"abstract":"<p><p>Liver fibrosis is a proposed risk factor for intracerebral hemorrhage (ICH) and a predictor of ICH-related mortality. However, its impact on functional outcomes and hemorrhage location remains unclear. We aimed to investigate whether liver fibrosis is associated with clinical outcomes and hematoma characteristics according to ICH location. Consecutive patients with ICH between July 2012 and November 2023 were retrospectively included. Favorable outcomes were defined as a modified Rankin Scale score of 0 to 1 at 3 months following stroke onset. We elucidated whether liver fibrosis, assessed by the Fibrosis-4 index (FIB-4 index), was associated with prognosis and hematoma volume in the entire ICH cohort, and separately in lobar and non-lobar ICH cohorts. Following screening of 608 consecutive ICH patients, 356 patients with ICH (entire cohort) who met the inclusion criteria (198 [56%] males, median age 73 years), including 69 with lobar ICH and 287 patients with non-lobar ICH, were identified. Similar to the entire ICH cohort, especially in the lobar ICH cohort, the FIB-4 index correlated negatively with favorable outcomes (prevalence ratio (PR) 0.823, 95% confidence interval (CI) 0.692-0.979, p = 0.027) and positively with hematoma volume (unstandardized coefficient 3.914, 95% CI 1.914-5.915, p < 0.001). Conversely, the FIB-4 index was associated with neither prognosis nor hematoma volume in the non-lobar ICH cohort. Liver fibrosis, as assessed by the FIB-4 index, is associated with unfavorable outcomes and hematoma volume in ICH, particularly in lobar ICH.</p>","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145722445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating emerging vascular biomarkers into clinical hypertension practice: Reflections on the hypertension research update and perspectives 2025. 将新兴血管生物标志物纳入高血压临床实践:对高血压研究进展和展望的思考[j]。
IF 4.6 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-10 DOI: 10.1038/s41440-025-02496-2
Takeshi Fujiwara, Shinji Kishimoto, Koichi Yamamoto
{"title":"Integrating emerging vascular biomarkers into clinical hypertension practice: Reflections on the hypertension research update and perspectives 2025.","authors":"Takeshi Fujiwara, Shinji Kishimoto, Koichi Yamamoto","doi":"10.1038/s41440-025-02496-2","DOIUrl":"https://doi.org/10.1038/s41440-025-02496-2","url":null,"abstract":"","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145722477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on "Peak nocturnal home blood pressure as an early and strong novel risk factor for stroke: the practitioner-based nationwide J-HOP Nocturnal BP study". 对“夜间家庭血压峰值作为中风的早期和强烈的新危险因素:基于医生的全国J-HOP夜间血压研究”的评论。
IF 4.6 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-05 DOI: 10.1038/s41440-025-02480-w
Jingman Wang, Lijuan Wu, Qiuyue Wang, Keke Wang
{"title":"Comment on \"Peak nocturnal home blood pressure as an early and strong novel risk factor for stroke: the practitioner-based nationwide J-HOP Nocturnal BP study\".","authors":"Jingman Wang, Lijuan Wu, Qiuyue Wang, Keke Wang","doi":"10.1038/s41440-025-02480-w","DOIUrl":"10.1038/s41440-025-02480-w","url":null,"abstract":"","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145677364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practical considerations for assessing nocturnal blood pressure peak: a response to Wang et al. 评估夜间血压峰值的实际考虑:对Wang等人的回应。
IF 4.6 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-05 DOI: 10.1038/s41440-025-02479-3
Satoshi Hoshide, Kazuomi Kario
{"title":"Practical considerations for assessing nocturnal blood pressure peak: a response to Wang et al.","authors":"Satoshi Hoshide, Kazuomi Kario","doi":"10.1038/s41440-025-02479-3","DOIUrl":"https://doi.org/10.1038/s41440-025-02479-3","url":null,"abstract":"","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145677418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hypertension Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1